Real-Time Polymerase Chain Reaction
(RT-PCR Test)
Highly sensitive molecular diagnostics for precision oncology — detecting fusion transcripts and Minimal Residual Disease with exceptional accuracy.
Our RT-PCR service identifies cancer-associated genetic alterations directly from blood and bone marrow, supporting early diagnosis, treatment monitoring, and relapse risk assessment across modern precision oncology programs.
Cancer Diagnosis and the Role of RT-PCR Test
A highly sensitive and specific molecular technique that has transformed the detection and monitoring of cancer.
Cancer continues to be a growing public health concern in India. According to the Indian Council of Medical Research–National Cancer Registry Programme (ICMR-NCRP), the number of cancer cases is projected to increase from approximately 1.46 million in 2022 to 1.57 million by 2025.
Early and accurate diagnosis is essential for improving patient outcomes. Advances in molecular diagnostic technologies, particularly Real-Time Polymerase Chain Reaction (RT-PCR Test), have transformed the detection and monitoring of cancer. RT-PCR is a highly sensitive and specific molecular technique capable of identifying cancer-associated genetic alterations and detecting Minimal Residual Disease (MRD) with exceptional accuracy.
By detecting known fusion transcripts and other disease-associated genetic markers, RT-PCR supports early diagnosis, treatment monitoring, therapeutic decision-making, and relapse risk assessment, making it an indispensable tool in modern precision oncology.
Why RT-PCR
- Highly sensitive, specific detection of cancer-associated genetic alterations.
- Minimal Residual Disease (MRD) monitoring with exceptional accuracy.
- Detection of known fusion transcripts and disease-associated markers.
- Support for treatment monitoring and relapse risk assessment.
PML-RARA Real-Time PCR Kits
Multiplex, one-step RT-PCR assays for the diagnosis and molecular monitoring of Acute Promyelocytic Leukemia (APL).
PML-RARA Qualitative Real-Time PCR Kit
The PML-RARA Qualitative Real-Time PCR Kit is an in vitro, multiplex, one-step RT-PCR assay developed for the qualitative detection of PML-RARA fusion transcripts (bcr1, bcr2, and bcr3) from RNA extracted from human peripheral blood or bone marrow aspirate samples.
The assay simultaneously amplifies the ABL1 internal control within a single reaction, ensuring reliable assessment of sample quality and accurate identification of PML-RARA fusion transcripts. It supports the diagnosis and molecular evaluation of Acute Promyelocytic Leukemia (APL) by providing dependable qualitative detection of disease-associated genetic alterations.
PML-RARA Quantitative Real-Time PCR Kit
The PML-RARA Quantitative Real-Time PCR Kit is an in vitro, multiplex, one-step RT-PCR assay designed for the specific differentiation and quantitative detection of PML-RARA fusion transcripts, including bcr1 (long)/bcr2 (variant) and bcr3 (short), from RNA extracted from human peripheral blood or bone marrow aspirate samples.
The assay simultaneously amplifies the ABL1 internal control within the same reaction, providing robust quality assurance and accurate quantification of PML-RARA transcripts. It supports the diagnosis and long-term molecular monitoring of Acute Promyelocytic Leukemia (APL) by enabling highly sensitive measurement of disease-associated fusion transcripts.
Life science innovators
come to CNC Path Lab
Ready to accelerate your clinical program? Our experts are here to help you design and execute the perfect laboratory strategy. Are you ready?